🔴 Context Therapeutics is trading 6% down with no specific catalyst identified

Context Therapeutics is trading 6.03% lower at $0.29 on October 13, 2026, with no specific company catalyst identified.

• The latest listed company release was September 9, about the first patient dosed in the CT-202 Phase 1 trial.
• The supplied market context reports XBI down 2.01% during the session, while major indexes were nearly flat; available evidence does not establish this as the cause of the sharper decline.